Serkan Yaras1 , Mehmet Demir2 , Sezgin Barutcu3 , Abdullah Emre Yıldırım4 , Selim Gurel5 , Enver Ucbilek1 , Ilkce Akgun Kurtulmus6 , Meral Akdogan Kayhan7 , Sezgin Vatansever8 , Haydar Adanir9 , Nilay Danis10 , Serkan Duman11 , Ilker Turan12 , Derya Ari7 , Sukran Kose13 , Huseyin Alkim14 , Muhsin Murat Harputluoglu15 , Feyza Dilber16 , Murat Akyildiz17 , Arif Mansur Cosar18 , Serdar Durak18 , Goktug Sirin19 , Ayse Kefeli20 , Hale Gokcan21 , Ufuk Avcioglu22 , Talat Ayyildiz22 , Orhan Sezgin1 , Mesut Akarsu23 , Dinc Dincer24 , Fatih Guzelbulut12 , Fulya Gunsar12 , Ulus Salih Akarca25 , Ramazan Idilman25 2Department of Gastroenterology, Faculty of Medicine, Mustafa Kemal University, Hatay, Turkiye
3Department of Medical Sciences, Faculty of Medicine Internal, Gaziantep University, Gaziantep, Turkiye
4Department of Gastroenterology, Memorial Bahcelievler Hospital, Istanbul, Turkiye
5Department of Internal Medicine, Faculty of Medicine, Uludag University, Bursa, Turkiye
6Department of Internal Medicine, Faculty of Medicine, Ege University, İzmir, Turkiye
7Department of Internal Medicine, Faculty of Health Sciences, Clinic of Gastroenterology, Ankara City Hospital, Ankara, Turkiye
8Department of Gastroenterology, Katip Celebi University, Ataturk Training and Research Hospital, İzmir, Turkiye
9Department of Internal Medicine, Faculty of Medicine, Akdeniz University, Antalya, Turkiye
10Department of Medicine, Division of Gastroenterology and Hepatology, Johns Hopkins University, USA
11Department of Gastroenterology, Faculty of Internal Medicine, Toros State Hospital, Mersin, Turkiye
12Department of Gastroenterology, Faculty of Medicine Ege University, Izmir, Turkiye
13Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkiye
14Department of Gastroenterology, Sisli Etfal Education and Research Hospital, Istanbul, Turkiye
15Department of Internal Medicine, Faculty of Medicine, Inonu University, Malatya, Turkiye
16Department of Gastroenterology, Faculty of Medicine Marmara University, Istanbul, Turkiye
17Department of Gastroenterology, Faculty of Medicine Koc University, Istanbul, Turkiye
18Department of Gastroenterology, Karadeniz Technical University School of Medicine, Trabzon, Turkiye
19Department of Gastroenterology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkiye
20Department of Gastroenterology, Faculty of Medicine, Tokat Gaziosmanpasa University, Gaziantep, Turkiye
21Department of Gastroenterology, Faculty of Medicine, Ankara University, Ankara, Turkiye
22Department of Gastroenterology, Faculty of Medicine, On Dokuz Mayıs University, Samsun, Turkiye
23Department of Gastroenterology, Faculty of Medicine, Dokuz Eylıl, Izmir, Turkiye
24Department of Gastroenterology, Faculty of Medicine, Akdeniz University, Antalya, Turkiye
25Departments of Gastroenterology and Pathology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkiye
Abstract
Background and Aim: The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC).
Material and Methods: Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study.
Results: All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per proto-col analysis. The SVR12 rates were statistically significant differences be-tween the patients who were i.v. drug users and non-user (88.0% vs. 98.8%,p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed.
Conclusion: GLE/PIB is an effective and tolerable treatment in patients with CHC.
